MedTrace Logo

Assessment of Ovarian Reserve in Female Cancer Survivors

NCT01062542 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2018-06-12

No results posted yet for this study

Summary

Chemotherapy can damage the ovaries and cause premature menopause. In women treated before the age of 40 years, menopause does not usually occur. We have very little information about the impact of chemotherapy on ovarian function in this particular group of women. In this study, we will check hormone blood tests and ultrasound tests of the ovaries to measure the reserve of eggs left in the ovaries after treatment in young survivors of breast cancer and childhood cancer. We will do the same tests in our comparison group. We can use these results to estimate the reduction in fertility in young cancer survivors.

Conditions

  • Breast Cancer Survivor
  • Pediatric Cancer Survivor

Interventions

PROCEDURE

Blood Draw and Ultrasound

Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.

Sponsors & Collaborators

  • Princess Margaret Hospital, Canada

    collaborator OTHER

  • Canadian Breast Cancer Foundation

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • David Hodgson, MD · University Health Network, Princess Margaret Hospital

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2018-03-31
Completion
2018-03-02

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01062542 on ClinicalTrials.gov